Alzheimer’s Blood Tests: How Close Is Routine Screening?

Nov 17, 2026 | Health Tech, Regulatory

Image Source: Generated by Google Gemini
Written by: LSDN Editorial Team
On behalf of: Life Science Daily News

For decades, confirming Alzheimer’s pathology meant an amyloid PET scan or a lumbar puncture. In 15 months, US regulators have cleared four blood tests that can do a similar job from a blood draw. Yet each Alzheimer’s blood test now on the US market is a diagnostic aid, not a screening tool. That distinction matters for anyone tracking where this market goes next.

The obvious next question is whether a simple test could soon screen healthy middle-aged adults, much as cholesterol tests do. The short answer is not yet. Every cleared test is limited to people who already have symptoms. The evidence, guidelines and treatments needed for population screening are still some years away.

Where Alzheimer’s Blood Tests Stand Today

Fujirebio’s Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio came first. The FDA cleared it on 16 May 2025 through the 510(k) pathway. It covers adults aged 55 and over with signs and symptoms of cognitive decline. In a study of 499 cognitively impaired adults, PET or cerebrospinal fluid testing confirmed 91.7% of positive results. It also confirmed 97.3% of negative results. Fewer than 20% of patients received an intermediate result.

Roche’s Elecsys pTau181, developed with Eli Lilly, followed in October 2025. Roche said it was the first blood test cleared to aid initial assessment in primary care. Its role is to rule out amyloid pathology in symptomatic adults aged 55 and over. Labcorp launched it nationwide on 11 February 2026, citing a 97.9% negative predictive value. Many symptomatic patients lack Alzheimer’s, the company noted, so ruling it out can matter as much as confirming it.

August 2026 brought two more clearances. C2N Diagnostics’ PrecivityAD2 was cleared on 20 August for symptomatic adults aged 40 and over. That is the youngest population covered by any cleared test. It uses high-resolution mass spectrometry to measure amyloid and tau ratios, which an algorithm combines into one result. It is intended to be ordered by clinicians experienced in evaluating cognitive impairment.

On 24 August, Roche announced 510(k) clearance for Elecsys pTau217, again developed with Lilly. Roche describes it as the first single-biomarker blood test to support both rule-in and rule-out assessment. It applies the same cutoffs in primary and specialty care, for symptomatic adults aged 55 and over.

Test Developer Biomarker Cleared population Intended role Cleared
Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio Fujirebio pTau217 to beta-amyloid 1-42 ratio Adults 55+ with signs and symptoms Aid to identify amyloid pathology; positive, negative or intermediate 16 May 2025
Elecsys pTau181 Roche, with Eli Lilly pTau181 Adults 55+ with symptoms, primary care Rule-out October 2025
PrecivityAD2 C2N Diagnostics Aβ42/40 and p-tau217 ratios by mass spectrometry Adults 40+ with symptoms Rule-in and rule-out 20 August 2026
Elecsys pTau217 Roche, with Eli Lilly pTau217 Adults 55+ with symptoms, primary and specialty care Rule-in and rule-out, same cutoffs 24 August 2026

 

Sources: FDA, Roche, C2N Diagnostics and Labcorp. Roche dates are announcement dates.

The direction of travel is clear: from specialist confirmation towards primary care triage. What has not changed is who the tests are for.

Diagnosis Is Not Screening

Every cleared Alzheimer’s blood test shares one boundary. Its intended use is assessing people who already show signs of cognitive decline. When it cleared Lumipulse, the FDA stated plainly that the test is not a screening tool or a stand-alone diagnostic. C2N and Roche describe their tests in the same terms, as aids used alongside clinical evaluation.

Screening symptom-free people would therefore need a different intended use, backed by different evidence. It would also need its own clinical guidelines and a reimbursement case.

Clinical guidance draws the same line. In July 2025, the Alzheimer’s Association published its first clinical practice guideline on blood-based biomarkers, aimed at specialist care. Tests with at least 90% sensitivity and 75% specificity can be used for triage. Tests reaching 90% on both measures can substitute for PET or cerebrospinal fluid testing.

Both recommendations are conditional and rest on low-certainty evidence. The panel also warned that tests are not interchangeable, since not all have been validated to the same standard. Primary care is being handled through a separate guideline process. Disease prevalence, pre-test probability and clinician experience all differ in that setting.

Performance in routine use can also slip. In February 2026, the FDA posted a Class II recall of Lumipulse plasma reagents, calibrators and controls. Fujirebio began it in December 2025. The reason given was falsely elevated results that could wrongly place patients in the positive or intermediate range.

A positive result in a person with memory complaints and one in a healthy 50-year-old mean very different things.

What the Evidence Says About Predicting Decline

The strongest prognostic data so far appeared in JAMA in July 2026. The study was presented at the Alzheimer’s Association International Conference in London. A Mass General Brigham team led by Rachel Buckley pooled six cohorts covering 2,684 cognitively unimpaired older adults. Over a median 5.4 years of follow-up, 478 people progressed to cognitive impairment.

Higher plasma p-tau217 levels tracked with higher risk. Very high levels were defined as more than 2.5 standard deviations above the mean. Adults in that band had an estimated 38% absolute risk of impairment within five years. Ten-year estimates were higher. However, the authors note that sparse data constrain those longer projections.

Risk stratification is not diagnosis. A 38% five-year risk also means most people in the top band did not decline in that window. The researchers say it is too soon for healthy people to seek the test. “Wait and get tested when you can potentially do something about it,” said senior author Dr Reisa Sperling.

Real-world data point the same way for symptomatic patients. An interim Swedish study at the same conference covered 1,310 patients with mild cognitive impairment or dementia and 165 physicians. After reviewing PrecivityAD2 results, primary care clinicians’ diagnostic accuracy rose from 65% to 93%. In a head-to-head comparison, that matched the 94% reached by dementia specialists who also saw the results.

Results prompted primary care clinicians to change their diagnosis in about 30% of patients. Lead author Dr Sebastian Palmqvist, of Lund University, said its main primary care value was ruling Alzheimer’s out.

Demand, meanwhile, is moving ahead of guidance. Clinicians report rising numbers of symptom-free people seeking tests, through their doctors or commercial laboratories. Washington University neurologist Dr Suzanne Schindler described the shift to National Geographic in October 2026. “Two years ago we very rarely saw asymptomatic individuals getting tested,” she said. “But that has really changed.”

The UK Picture: Memory Clinics First, Screening Later

In the UK, blood tests are not yet part of routine NHS diagnosis for Alzheimer’s disease. The Blood Biomarker Challenge is the main effort to change that. It is backed by Alzheimer’s Society, Alzheimer’s Research UK, the NIHR, Gates Ventures and People’s Postcode Lottery. Its aim is routine NHS use of an Alzheimer’s blood test by 2029.

Its ADAPT trial is led by Professor Jonathan Schott and Dr Ashvini Keshavan at UCL. It is testing p-tau217 in around 1,100 people across 20 NHS memory clinics. The team hopes to lift diagnostic accuracy from about 70% to over 90%, with a test costing around £100. Participants receive results within three months or after 12 months, so the trial can show whether earlier disclosure changes care.

The second project is Dementias Platform UK’s READ-OUT study, co-led by Oxford Health NHS Foundation Trust. It is assessing whether a wider panel of blood biomarkers can work alongside existing memory clinic assessments. READ-OUT passed its 1,000th participant in July 2026, across 33 recruitment sites. More than 3,000 volunteers are expected to take part.

Government funding is now building on that work. In October 2025, ministers announced the Dementia Patient Flow R&I Challenge with £5 million of initial funding. On 2 October 2026, UK Research and Innovation launched the Dementia Challenge, backed by up to £80 million. One of its nine projects will integrate the READ-OUT biomarker panel into routine NHS memory services. The challenge targets 92% of people diagnosed within 18 weeks of referral, up from around 60% today.

In Wales, Health Technology Wales published a topic exploration report on PrecivityAD2 in February 2026. It noted the test holds UK regulatory approval as an in vitro diagnostic. However, it found no published studies measuring patient-relevant outcomes and no UK-specific economic evidence.

Capacity is the harder constraint. In 2021, Alzheimer’s Research UK and the Royal College of Psychiatrists surveyed old age psychiatry services. Only 6% could fully meet NICE guidance on access to biomarker tests. A May 2026 study in Age and Ageing still cites that figure. Fewer than a third of the 172 old age psychiatrists it surveyed had used biomarkers.

All of this UK work concerns faster, more accurate diagnosis in memory clinics. None of it is population screening.

What Has to Happen Before Alzheimer’s Blood Tests Can Screen

Six conditions stand between today’s diagnostic use and routine screening of healthy adults.

  1. A treatment worth screening for. Prevention trials in symptom-free, amyloid-positive people are the gating evidence. Lilly’s TRAILBLAZER-ALZ 3 is testing donanemab in preclinical Alzheimer’s, with an estimated 2,996 participants. Its registry entry gives an estimated primary completion of November 2027. Eisai’s AHEAD 3-45 trial of lecanemab completed enrolment in October 2024.
  2. A new intended use. No Alzheimer’s blood test is cleared for people without symptoms. Screening claims would need fresh regulatory submissions and supporting data.
  3. Primary care and screening guidelines. Neither exists yet for blood biomarkers. The Alzheimer’s Association primary care guideline is still in development.
  4. Health economics and reimbursement. Payers will need evidence that accurate diagnosis has value on its own, not only as a gateway to anti-amyloid drugs. A 2026 Milken Institute report, based on 32 expert interviews, urged US payers and health systems to act now.
  5. Downstream capacity. Positive results need confirmatory testing, specialist review, infusion capacity and MRI safety monitoring.
  6. Disclosure and ethics. Screening would demand counselling, careful handling of false positives and attention to insurance implications.

Both prevention trials already show what blood tests can do in this setting. TRAILBLAZER-ALZ 3 requires a p-tau blood result consistent with amyloid pathology for entry. AHEAD 3-45 used plasma ratios as a prescreen. According to Eisai, this cut PET screen failures from more than 70% to under 30%. The wider late-stage field is tracked in the Neurodegeneration Pipeline 2026 review.

So How Close Is It?

The cleared Alzheimer’s blood tests are already changing diagnosis for people with symptoms in the US. The UK, meanwhile, is targeting routine memory clinic use by 2029. Routine screening of healthy adults is a different proposition altogether.

Its earliest realistic trigger is positive prevention trial data, not expected before late 2027. New regulatory submissions, guidelines and payer decisions would then have to follow. On current evidence, population screening looks like a next-decade question rather than a next-year one.

Frequently Asked Questions

Is there an FDA-approved Alzheimer’s blood test?

Strictly, none is approved. Four have been cleared by the FDA: Lumipulse, Elecsys pTau181, PrecivityAD2 and Elecsys pTau217. All are cleared only for people with signs or symptoms of cognitive decline.

Can a healthy person get an Alzheimer’s blood test?

Some laboratories will run the tests, and demand from symptom-free people is rising. Alzheimer’s Association guidance advises against testing people without cognitive symptoms outside research. A positive result may cause anxiety and further testing without changing care.

When will Alzheimer’s blood tests be available on the NHS?

The Blood Biomarker Challenge aims for routine NHS use by 2029, for people already referred to memory services. That target covers diagnosis, not population screening.

    References:
    1. US Food and Drug Administration (2025). FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease. https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease
    2. Palmqvist S, Whitson HE, Allen LA, et al. (2025). Alzheimer’s Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer’s disease within specialized care settings. Alzheimer’s & Dementia 21(7):e70535. PMID 40729527. https://doi.org/10.1002/alz.70535
    3. Buckley RF, et al. (2026). Prognostic Value of Blood-Based P-Tau217 Levels for Progression to Cognitive Impairment. JAMA 336(11):950. https://doi.org/10.1001/jama.2026.12556
    4. UK Research and Innovation (2026). £80m challenge for faster, better dementia diagnosis launched. https://www.ukri.org/news/80m-challenge-for-faster-better-dementia-diagnosis-launched/
    5. Hazan J, Mealing M, Lorencatto F, et al. (2026). Factors influencing implementation of an Alzheimer’s disease blood test among UK old age psychiatrists. Age and Ageing 55(5):afag117. https://doi.org/10.1093/ageing/afag117
    6. C2N Diagnostics (2026). FDA Clears C2N Diagnostics’ PrecivityAD2: First Alzheimer’s Blood Test for Adults with Cognitive Symptoms as Young as 40. BusinessWire. https://www.businesswire.com/news/home/20260820868989/en/FDA-Clears-C2N-Diagnostics-PrecivityAD2-First-Alzheimers-Blood-Test-for-Adults-with-Cognitive-Symptoms-as-Young-as-40
    7. Alzheimer’s Association (2026). Statement on FDA Clearance of Elecsys pTau217 Blood Test for Alzheimer’s Diagnosis. https://www.alz.org/news/2026/fda-clearance-elecsys-ptau217-blood-test-alzheimers
    8. Alzheimer’s Association (2026). AAIC 2026: Alzheimer’s blood test could bring highly accurate diagnosis into everyday clinical care. https://aaic.alz.org/downloads2026/Bloodbiomarkers.pdf
    9. ClinicalTrials.gov (2026). NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer’s Disease (TRAILBLAZER-ALZ 3). https://clinicaltrials.gov/study/NCT05026866
    10. US Food and Drug Administration (2026). Class 2 Device Recall: Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio (Z-1307-2026). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?id=217946
    All content is published for informational purposes only and does not constitute medical, legal, or investment advice. For more information, see our Terms and Conditions.

    Articles that may be of interest

    Articles that may be of interest